SCHEMBL2014161

SCHEMBL2014161

CCOC(=O)COC1CCN(C(=O)CCN2Cc3cc(C(=N)NO)ccc3C2=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 5/20 0.45
ITGA2B P08514 5/20 0.45
ALDH1A1 P00352 2/20 0.35
POLB P06746 2/20 0.35
PLA2G1B P04054 1/20 0.35
GFER P55789 1/20 0.35
ATG4B Q9Y4P1 1/20 0.35
TSHR P16473 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
MAPT P10636 1/20 0.34
TNF P01375 2/20 0.33
BLM P54132 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
AOC3 Q16853 2/20 0.33
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM1 P11229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008734 0.92 ITGB3 (0.46) ITGB3ITGA2BPOLBTSHRMEN1
SCHEMBL2009764 0.87 ITGB3 (0.44) ITGB3ITGA2BALDH1A1POLBPLA2G1B
SCHEMBL2010165 0.83 ITGB3 (0.38) ITGB3ITGA2BALDH1A1POLBPLA2G1B
SCHEMBL2007714 0.82 ITGB3 (0.54) ITGB3ITGA2BAOC3
SCHEMBL2010746 0.81 ITGB3 (0.44) ITGB3ITGA2BALDH1A1TSHRMEN1
SCHEMBL2009033 0.81 ITGB3 (0.46) ITGB3ITGA2BPOLBMEN1KMT2A
SCHEMBL2008084 0.78 ITGB3 (0.45) ITGB3ITGA2BALDH1A1POLBTSHR
SCHEMBL2011706 0.78 ALOX15 (0.47) ITGB3ITGA2BALDH1A1HDAC6MEN1
SCHEMBL2009031 0.77 ITGB3 (0.56) ITGB3ITGA2BALDH1A1POLBMEN1
SCHEMBL2008869 0.74 MAPK1 (0.39) ITGB3ITGA2BALDH1A1AOC3MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US claimed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US claimed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US claimed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US claimed
US-7964628-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-06-21 US disclosed
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-10-07 US disclosed
US-7759387-B2 Fibrinogen receptor antagonists and their use PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-07-20 US disclosed
US-20070021489-A1 Fibrinogen receptor antagonists and their use NICHOLAS PIRAMAL INDIA LIMITED (IN) 2007-01-25 US disclosed
EP-1677783-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE Nicholas Piramal India Limited (IN) 2006-07-12 EP disclosed
WO-2005035495-A2 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE NICHOLAS PIRAMAL INDIA LIMITED (IN) 2005-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256161-A1 FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE FGB, F13B, F2 ITGB3 169/4885ITGA2B 63/4885ALDH1A1 2548/4885
US-20070021489-A1 Fibrinogen receptor antagonists and their use FGB, F13B, F2 ITGB3 169/4885ITGA2B 63/4885ALDH1A1 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.